E64-DRCR Protocol AC-Aflibercept Monotherapy or Bevacizumab First for DME- Dr. Chirag Jhaveri

Dr. Jhavery discusses results of DRCR Retina Protocol AC study which compared DME response to anti-VEGF injections in patients who received Aflibercept monotherapy vs those who started with Bevacizumab first and then switched to Aflibercept if needed. Discussed article: Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14. PMID: 35833805.

Episode metadata supplied by the publisher feed · Published Oct 30, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

E64-DRCR Protocol AC-Aflibercept Monotherapy or Bevacizumab First for DME- Dr. Chirag Jhaveri

0:00 34:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Retina Channel Podcast?

This episode is 34 minutes long.

When was this The Retina Channel Podcast episode published?

This episode was published on October 30, 2022.

Can I download this The Retina Channel Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!